News

A DESTINY-PanTumor02 trial update reveals the anti-tumor efficacy of trastuzumab deruxtecan in patients with HER2-expressing, advanced solid tumors.

The VENTANA PD-L1 Assay can now be used to detect PD-L1 expression in patients with non–small cell lung cancer to determine eligibility for treatment with cemiplimab.

Aditya Bardia, MD, MPH, discussed potential second-line therapies for patients with metastatic triple-negative breast cancer.

In the wave of its major influence on these malignancies, anti-HER2 therapy for various cancers—notably colorectal cancer —has been thoroughly investigated.

With a broadened FDA label for abemaciclib, patients high-risk breast cancer can now be categorized based only on nodal status, tumor size, and tumor grade.

Findings from the phase 3 CONTACT-03 fail to add evidence supporting immune checkpoint inhibitor and tyrosine kinase inhibitor combination therapy for advanced renal cell carcinoma.

At a live virtual event, Andrew Kuykendall, MD, discussed the rationale and data for the use of pacritinib in patients with high-risk primary myelofibrosis.

Brian A. Jonas, MD, PhD, discusses novel biomarkers being explored in acute myeloid leukemia, including e-selectin, which Jonas believes is very promising.

Benjamin Philip Levy, MD, discussed systemic therapies for patients with ALK-rearranged metastatic non–small cell lung cancer and data from recent trials in this space.

During a live Twitter Spaces event hosted by Targeted Oncology, Naveen Pemmaraju, MD, explained key abstracts from ASH 2022 and how these data have influenced recent approvals in the hematology field.

The FDA has planned a regular review of the biologic license application for cosibelimab for the treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.

JWATM214, an autologous T-cell immunotherapy candidate drug targeting GPC-3 for patients with advanced hepatocellular carcinoma, is now being investigated in a phase 1 trial.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

YB-200, an investigational CEACAM antibody, has caught the attend of the FDA.

The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.

Looking at a subgroup analysis of patients with hormone receptor-positive and HER2-negative breast cancer on endocrine therapy, researchers saw promising results but worrying disparities between non-Hispanic White patients and non-Hispanic Black patients.

Data from the second interim analysis of the phase 3 MAGNITUDE study showed that the addition of niraparib to abiraterone acetate and prednisone prolonged survival for patients with metastatic castration-resistant prostate cancer with BRCA mutations.

With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?

From the new approval for sacituzumab govitecan for a breast cancer subgroup to dostarlimab for dMMR advanced endometrial, February 2023 was an important month of FDA activity.

Charles Geyer, MD, discusses the potential impact of adjuvant olaparib on the treatment landscape for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Retrospective research shows a link behind low household income and recurrence score and survival, but there is more to uncover behind the association between socioeconomic determinants of health and tumor biology.

In an interview with Targeted Oncology, Zahra Mahmoudjafari, PharmD, BCOP, discussed the post hoc analysis from the REACH2 trial and highlighted the key takeaways.

Jennifer R. Brown, MD, PhD, discusses what potential advancements are bringing excitement into the chronic lymphocytic leukemia space.

Efficacy findings from CheckMate-76 have led the FDA to accept the supplemental biologics license application and the EMA to validate the type II variation marketing authorization application for nivolumab alone in stage IIB or IIC melanoma.

Yann-Alexandre Vano, MD, explains the methods and design of the phase 2 BIONIKK trial for patients with renal cell carcinoma.

Zev A. Wainberg, MD, discusses recent findings from the NAPOLI 3 trial which were presented at the 2023 Gastrointestinal Cancers Symposium.

The phase 3 PhALLCON trial showed a trend toward event-free survival in patients with Philadelphia chromosome positive acute lymphoblastic leukemia when treated with ponatinib compared with imatinib.

Based on the FDA’s review of a new drug application, a phase 2 study will evaluate the safety and efficacy of azeliragon for patients with glioblastoma.

Data from the phase 3 DeFi trial showed that nirogacestat led to a 71% reduction in the risk of disease progression compared with placebo for adult patients with desmoid tumors. Now, the FDA has granted a priority review to the new drug application for nirogacestat.